StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) stock

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.53−0.25 (-1.33%)

Close on Nov 18, 2026Market cap $1.67BP/E –Yield –

Braveheart Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$30.15M–
Q2 FY2026Jun 30, 2026-$15.88M–
Q3 FY2025Sep 30, 2025-$59.29M–
Q2 FY2025Jun 30, 2025-$381.00K–

More Braveheart Bio figures

See a number that looks wrong?